Base Therapeutics
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Base Therapeutics (贝斯生物） is a Shanghai-based healthtech company founded in 2021 by CEO Dr. Forrest Xu, focused on gene editing and cell therapy. Its core asset is the AccuBase Base Editing System, a proprietary high-fidelity base editor said to operate free of third-party intellectual property worldwide, with no off-target editing effects. The company develops therapies for cancers, autoimmune diseases and chronic metabolic diseases, and in November 2024 its base-edited NK cell product - billed as the world's first - received clinical trial approvals from both US and Chinese regulators.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Founded in Shanghai
Dr. Forrest Xu founded Base Therapeutics in Shanghai to develop gene editing and cell therapy products, anchored by the AccuBase Base Editing System.
- Hong Kong expansion and A2 round
The company opened an office and R&D centre in Hong Kong in July 2024 to drive global expansion, and completed its A2 funding round in September 2024 to support R&D.
- World-first base-edited NK cell product cleared
In November 2024 Base Therapeutics' base-edited NK cell product - described as the world's first - received clinical trial approvals from both US and Chinese regulatory authorities.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.